SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2-3 trials

Key Points

• This research aims to evaluate the SLE-DAS responder index as a reliable outcome measure in SLE trials.
• Assessment of the SLE-DAS RI in phase 2-3 trials of anifrolumab.
• Comparison of SLE-DAS RI with other efficacy endpoints.
• Evaluation of improvements in patient-reported outcomes.
• SLE-DAS RI demonstrates robust performance as an efficacy endpoint.
• Associated with sustained disease control over time.
• Facilitates accurate identification of meaningful outcomes in trial design.

Abstract